MicroRNA-24-3p Targets Notch and Other Vascular Morphogens to Regulate Post-ischemic Microvascular Responses in Limb Muscles.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
03 Mar 2020
Historique:
received: 28 01 2020
revised: 19 02 2020
accepted: 20 02 2020
entrez: 7 3 2020
pubmed: 7 3 2020
medline: 15 12 2020
Statut: epublish

Résumé

MicroRNAs (miRs) regulate complex processes, including angiogenesis, by targeting multiple mRNAs. miR-24-3p-3p directly represses eNOS, GATA2, and PAK4 in endothelial cells (ECs), thus inhibiting angiogenesis during development and in the infarcted heart. miR-24-3p is widely expressed in cardiovascular cells, suggesting that it could additionally regulate angiogenesis by acting on vascular mural cells. Here, we have investigated: 1) new miR-24-3p targets; 2) the expression and the function of miR-24-3p in human vascular ECs; 3) the impact of miR-24-3p inhibition in the angiogenesis reparative response to limb ischemia in mice. Using bioinformatics target prediction platforms and 3'-UTR luciferase assays, we newly identified Notch1 and its Delta-like ligand 1 (Dll1) to be directly targeted by miR-24-3p. miR-24-3p was expressed in human ECs and pericytes cultured under normal conditions. Exposure to hypoxia increased miR-24-3p in ECs but not in pericytes. Transfection with a miR-24-3p precursor (pre-miR-24-3p) increased miR-24-3p expression in ECs, reducing the cell survival, proliferation, and angiogenic capacity. Opposite effects were caused by miR-24-3p inhibition. The anti-angiogenic action of miR-24-3p overexpression could be prevented by simultaneous adenovirus (Ad)-mediated delivery of constitutively active Notch intracellular domain (NICD) into cultured ECs. We next demonstrated that reduced Notch signalling contributes to the anti-angiogenic effect of miR-24-3p in vitro. In a mouse unilateral limb ischemia model, local miR-24-3p inhibition (by adenovirus-mediated miR-24-3p decoy delivery) restored endothelial Notch signalling and increased capillary density. However, the new vessels appeared disorganised and twisted, worsening post-ischemic blood perfusion recovery. To better understand the underpinning mechanisms, we widened the search for miR-24-3p target genes, identifying several contributors to vascular morphogenesis, such as several members of the Wingless (Wnt) signalling pathway, β-catenin signalling components, and VE-cadherin, which synergise to regulate angiogenesis, pericytes recruitment to neoformed capillaries, maturation, and stabilization of newly formed vessels. Among those, we next focussed on β-catenin to demonstrate that miR-24-3p inhibition reduces β-catenin expression in hypoxic ECs, which is accompanied by reduced adhesion of pericytes to ECs. In summary, miR-24-3p differentially targets several angiogenesis modulators and contributes to autonomous and non-autonomous EC crosstalk. In ischemic limbs, miR-24-3p inhibition increases the production of dysfunctional microvessels, impairing perfusion. Caution should be observed in therapeutic targeting of miR-24-3p.

Identifiants

pubmed: 32138369
pii: ijms21051733
doi: 10.3390/ijms21051733
pmc: PMC7084374
pii:
doi:

Substances chimiques

3' Untranslated Regions 0
MIRN24 microRNA, human 0
MicroRNAs 0
NOTCH1 protein, human 0
Receptor, Notch1 0
Receptors, Notch 0
beta Catenin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : British Heart Foundation
ID : RG/15/5/31446
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have no conflicting financial interest.

Références

Development. 1991 Apr;111(4):1029-43
pubmed: 1879348
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
J Cell Biol. 2003 Jun 23;161(6):1163-77
pubmed: 12810700
Adv Exp Med Biol. 2018;1109:111-124
pubmed: 30523593
Nat Cell Biol. 2015 Sep;17(9):1145-57
pubmed: 26302406
Cancer Lett. 2019 Jan;440-441:211-222
pubmed: 30393198
Circ Res. 2008 Jul 18;103(2):e15-26
pubmed: 18566344
Nat Cell Biol. 2011 Aug 14;13(10):1244-51
pubmed: 21841793
Development. 2005 Apr;132(8):1819-30
pubmed: 15772135
Genes Dev. 2000 Jun 1;14(11):1343-52
pubmed: 10837027
Trends Endocrinol Metab. 2015 Sep;26(9):502-8
pubmed: 26197955
Am J Transl Res. 2016 Jul 15;8(7):3179-87
pubmed: 27508039
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
J Exp Med. 2011 Mar 14;208(3):549-60
pubmed: 21383058
Cardiovasc Res. 2001 Feb 16;49(3):507-21
pubmed: 11166264
Mol Ther. 2009 Jun;17(6):1109-15
pubmed: 19352324
Biochim Biophys Acta. 2009 Feb;1793(2):290-9
pubmed: 19000719
Nature. 1997 Nov 27;390(6658):410-3
pubmed: 9389482
J Biol Chem. 2011 Apr 15;286(15):13741-53
pubmed: 21349836
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Development. 2014 Apr;141(8):1757-66
pubmed: 24715464
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8287-92
pubmed: 21536891
PLoS One. 2009;4(4):e5033
pubmed: 19343226
J Cell Mol Med. 2008 Sep-Oct;12(5A):1426-31
pubmed: 18624759
Sci Rep. 2015 Nov 05;5:16151
pubmed: 26537366
J Angiogenes Res. 2010 Jan 26;2(1):3
pubmed: 20298529
Circulation. 2011 Aug 9;124(6):720-30
pubmed: 21788589
J Cell Biochem. 2007 Nov 1;102(4):840-7
pubmed: 17891779
Mol Ther. 2013 Jul;21(7):1390-402
pubmed: 23774796
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Nat Rev Mol Cell Biol. 2011 Aug 23;12(9):551-64
pubmed: 21860391
Genome Res. 2013 Apr;23(4):604-15
pubmed: 23335364
Clin Biochem Rev. 2017 Nov;38(3):131-142
pubmed: 29332977
Mol Cancer. 2014 Feb 11;13:28
pubmed: 24517586
Circ Res. 2012 Feb 17;110(4):530-5
pubmed: 22282195
Dev Cell. 2005 Nov;9(5):617-28
pubmed: 16256737
Nat Commun. 2014 Oct 31;5:5214
pubmed: 25358394
Angiogenesis. 2019 Feb;22(1):167-183
pubmed: 30238211
Blood. 2008 Sep 1;112(5):1720-9
pubmed: 18559979
Nature. 2012 Mar 18;484(7392):110-4
pubmed: 22426001
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9462-7
pubmed: 12080144
J Am Soc Nephrol. 2014 Dec;25(12):2717-29
pubmed: 24854275
J Cell Biochem. 2012 Feb;113(2):629-39
pubmed: 21956839
F1000Prime Rep. 2015 Mar 03;7:26
pubmed: 25926977
Cancer Metastasis Rev. 2000;19(1-2):1-5
pubmed: 11191048
Cell Rep. 2014 Aug 21;8(4):1077-92
pubmed: 25131208
J Cell Biol. 2010 Apr 19;189(2):325-38
pubmed: 20404113
Dev Cell. 2009 Jan;16(1):70-82
pubmed: 19154719
Dev Cell. 2009 Feb;16(2):196-208
pubmed: 19217422
Gene. 2010 Feb 1;451(1-2):1-5
pubmed: 19944134
Circ Res. 2011 Sep 30;109(8):894-906
pubmed: 21868695
Biochim Biophys Acta. 2016 Feb;1863(2):303-13
pubmed: 26592459
Nature. 2007 Feb 15;445(7129):776-80
pubmed: 17259973
Vasc Med. 2008 Aug;13(3):281-91
pubmed: 18687766
Mol Ther Nucleic Acids. 2016 Aug 23;5(8):e354
pubmed: 27741223
Dev Cell. 2017 Mar 27;40(6):552-565.e5
pubmed: 28350988
Microcirculation. 2019 Aug;26(6):e12549
pubmed: 30974486

Auteurs

Micol Marchetti (M)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.

Marco Meloni (M)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.

Maryam Anwar (M)

National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.

Ayman Al Haj Zen (AAH)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.

Graciela Sala-Newby (G)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.

Sadie Slater (S)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.

Kerrie Ford (K)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.

Andrea Caporali (A)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.
BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH164TJ, UK.

Costanza Emanueli (C)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol BS2 8HW, UK.
National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH